Brief: Bionomics Reports Topline Results In Prevail Phase 2 Study Of BNC210
19/12/2022 01:21
Dec 19 (Reuters) - Bionomics Ltd BNO.AX :
* REPORTS TOPLINE RESULTS IN PREVAIL PHASE 2 STUDY OF BNC210
IN
SOCIAL ANXIETY DISORDER
* BNC210 FOR TREATMENT OF SOCIAL ANXIETY DISORDER DID NOT
MEET
PRIMARY ENDPOINT
Source text for Eikon: ID:nASX9xg0Hl
Further company coverage: BNO.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Bionomics
See all newsBrief: Bionomics Announces Intention To Delist From The Australian Securities Exchange (ASX)
Brief: Bionomics Announces Its Intention To De-List From Australian Securities Exchange
Australia's Bionomics plunges to record low after co announces ASX delisting
Brief: Bionomics Ltd Seeks Trading Halt
Brief: Bionomics Says Alan Fisher Appointed Chair Of Board Of Directors